The Asia Pacific Orthopedic Regenerative Surgical Products Market would witness market growth of 4.8% CAGR during the forecast period (2023-2030).
A rising number of medical professionals are using orthobiologics in their routine care. With a growing body of research to support them, these doctors have begun using this approach to treat conditions like osteoarthritis and tendinopathy. They provide treatments like the injection of platelet-rich plasma, mesenchymal stem cells, and biomaterials, which are biological substances like autologous chondrocytes (patient-derived cells that produce cartilage), bovine collagen, bone matrix, and proteins.
These orthobiologics are typically used as conservative treatments, which means they are utilized as a less intrusive substitute for surgery or as a backup plan when all other options have failed. Accurate drug dosage delivery is also made possible by several advances, including reservoir-type orthobiologics and improved and miniaturized ortho biologics patches. The development of technology that enables the delivery of targeted organ medication is another factor contributing to the forecasted growth in demand for orthobiologics.
Increased R&D research, technological developments, and the expanding use of innovative technologies like stem cells, viscosupplements, and platelet rich plasma (PRP) therapies are all expected to increase demand in the market. With a focus on the restoration and repair of harmed tissues, trauma, and osteoarthritis healing, stem cell as well as PRP-based treatments are at the forefront of regenerative medicine research.
According to the National Library of Medicine, numerous studies have showed significant heterogeneity, and the overall incidence of osteoarthritis (OA) was 16.05. In South Asia, the pooled prevalence of osteoarthritis was 16.4%, and in East Asia and the Pacific, it was 15.7%. In India, there were 62.35 million people with OA in 2019. From 4,895 in 1990 to 5313 in 2019 per 100,000 people, the age-standardized prevalence of OA rose significantly in the nation. The concerned organizations of the region have thus increased their efforts to raise awareness of osteoarthritis. This is because patients with knee OA should practice self-management, weight control, OA education, and regular exercise while receiving conservative care to improve their condition. Therefore, the increasing prevalence of osteoarthritis will aid in the development of the regional market.
The China market dominated the Asia Pacific Orthopedic Regenerative Surgical Products Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $381.7 million by 2030. The Japan market would showcase a CAGR of 4.1% during (2023 - 2030). Additionally, The India market is expected to witness a CAGR of 5.4% during (2023 - 2030).
Based on End-Use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Others. Based on Application, the market is segmented into Joint Reconstruction, Cartilage & Tendon Repair, Trauma Repair, Orthopedic Pain Management and Others. Based on Product, the market is segmented into Viscosupplements, Allografts (Amniotic Products and Others), Synthetic and Cell-based. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Orthopedic Regenerative Surgical Products Market is Projected to reach USD 5.4 Billion by 2030, at a CAGR of 4.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include MiMedx Group, Inc., Vericel Corporation, Baxter International, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, Smith & Nephew, Arthrex, Inc., BioTissue Holdings, Inc., VSY Biotechnology GmbH and Aptissen S.A.
By End-use
By Application
By Product
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 